Conjugation Linkers Cell Binding Molecule-Drug Conjugates Hangzhou DAC Biotech
Summary
USPTO published patent application US20260108619A1 filed by Hangzhou DAC Biotech Co., Ltd. on October 14, 2025. The application covers novel conjugation linkers having propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl groups, and their use for attaching cytotoxic agents to cell-binding molecules such as antibodies to form antibody-drug conjugates (ADCs).
“The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108619A1 for conjugation linkers used in the manufacture of cell binding molecule-drug conjugates, such as antibody-drug conjugates (ADCs). The application specifically covers linkers containing propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl groups for attaching cytotoxic agents to targeting molecules.
Manufacturers and developers of targeted cancer therapeutics, particularly ADC products, should note this published application as it may indicate competitive activity in the linker technology space. The named inventors—Yongxin Robert Zhao, Qingliang Yang, Yuanyuan Huang, Hangbo Ye, and Huihui Guo—may be involved in related research programs or competing patents.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS
Application US20260108619A1 Kind: A1 Apr 23, 2026
Assignee
Hangzhou DAC Biotech Co., Ltd.
Inventors
Yongxin Robert Zhao, Qingliang Yang, Yuanyuan Huang, Hangbo Ye, Huihui Guo
Abstract
The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.
CPC Classifications
A61K 47/6803 A61K 47/68031 A61K 47/68035 A61K 47/6829 A61K 47/6831 A61K 47/6855 A61K 47/6863 A61K 47/6883 A61K 47/6889
Filing Date
2025-10-14
Application No.
19357900
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.